Position in INO
as of Mar 31, 2026
· filed May 18, 2026
Position Value
$2,557,987
-$25,926 QoQ
Shares Held
1,470,108
-1.0% QoQ
Ownership
1.79%
of shares outstanding
% of Portfolio
0.16%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in INO Over Time
Shares Held
Position Value (USD)
Derivatives in INO
reported options exposure · as of Dec 31, 2025CallValue
$131,370
CallShares
75,500
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026ADAR1 Capital Management, LLC holds $1,362,941,740 across 211 Biotechnology names. INO ranks #88 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
1,394,019 | $155,224,015 | |
| 2 | PTGX |
Protagonist Therapeutics, Inc
|
994,119 | $104,780,142 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
3,285,906 | $91,019,596 | |
| 4 | IMVT |
Immunovant, Inc.
|
2,679,010 | $66,546,608 | |
| 5 | TERN |
Terns Pharmaceuticals, Inc.
|
914,699 | $48,222,931 | |
| 6 | CYTK |
Cytokinetics Inc
|
632,556 | $41,691,765 | |
| 7 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
1,139,331 | $41,380,501 | |
| 8 | DNLI |
Denali Therapeutics Inc.
|
1,871,455 | $35,931,936 |
All Filings in INO
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,557,987 | 1,470,108 | Shares | Sole | 2026-05-18 | |
| 2025-12-31 | $131,370 | 75,500 | Call | Sole | 2026-02-18 | |
| 2025-12-31 | $2,583,913 | 1,485,008 | Shares | Sole | 2026-02-18 | |
| No filing history on record for this holder in this stock. | ||||||